Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid a roiling trade war between the US ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

Several major drugmakers are counting on their manufacturing flexibility to counter potential disruptions from tariffs ...

Merck & Co. Inc. closed 41.34% below its 52-week high of $134.63, which the company achieved on June 25th.

The stock's rise snapped a three-day losing streak.

A biotech company is suing to block Merck & Co. from launching an easier-to-use version of its blockbuster cancer treatment ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

Revenue for Q1 2025 reached $15.5 billion, driven by robust performances in oncology, animal health, and new product launches. The company reaffirmed its focus on research and development as a key ...

Julie Hyman provides an overview of the top stories of the trading day in just 60 seconds on Yahoo Finance's Market Minute. Merck & Company (MRK) warns investors that it expects a $200 million hit ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Merck is growing pharma sales and expanding margins, led by strong KEYTRUDA performance and cost discipline. Read more about ...